Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Editas Medicine
(NQ:
EDIT
)
3.870
+0.080 (+2.11%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Editas Medicine
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Analyst Expectations for Editas Medicine's Future
August 29, 2023
Via
Benzinga
These 2 Stocks Could Skyrocket by 54% and 119%, According to Wall Street
August 23, 2023
Is the Street's optimism justified here?
Via
The Motley Fool
Expert Ratings for Editas Medicine
August 03, 2023
Via
Benzinga
Editas Medicine Announces Second Quarter 2023 Results and Business Updates
August 02, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces Second Quarter 2023 Results Conference Call and Corporate Update
July 26, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Is Editas Medicine Stock a Buy Now?
June 28, 2023
The fortunes of this once-promising biotech company have changed in the past year.
Via
The Motley Fool
What 6 Analyst Ratings Have To Say About Editas Medicine
June 13, 2023
Via
Benzinga
Editas Medicine's Return On Capital Employed Insights
May 19, 2023
Via
Benzinga
Editas Medicine and Azzur Group Expand Partnership to Accelerate Editas’ Manufacturing Capabilities for Advancing the EDIT-301 Program Through Approval to Commercialization
July 27, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Strengthens Executive Leadership Team with Appointment of Linda C. Burkly, Ph.D., as Chief Scientific Officer
July 24, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
This 1 Problem Could Sink at Least 4 Gene-Editing Stocks
June 29, 2023
Reaching profitability could be harder than investors expect.
Via
The Motley Fool
What Is CRISPR And Why Should Your Portfolio Care?
June 25, 2023
CRISPR Therapeutics continues to be at the forefront of CRISPR-based therapeutics development. It's the first, and largest, but not the only player.
Via
Talk Markets
After It Fell 15% in 1 Day, Should You Buy The Dip on Editas Stock?
June 20, 2023
It's not about to start making money anytime soon.
Via
The Motley Fool
Why John Wiley & Sons Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
June 15, 2023
Gainers SCWorx Corp. (NASDAQ: WORX) shares jumped 281% to $0.8396.
Via
Benzinga
2 Short-Squeeze Candidates That Could Go Parabolic
June 15, 2023
Editas Medicine and Bluebird Bio have been favorite targets for short-sellers lately.
Via
The Motley Fool
Gambling.com, Editas Medicine And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
June 15, 2023
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
Editas Medicine Announces Pricing of Offering of Common Stock
June 14, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces Offering of Common Stock
June 14, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For June 13, 2023
June 13, 2023
Via
Benzinga
5 Stocks to Buy With Explosive 500% Potential
June 12, 2023
Take advantage of a bullish change in investor sentiment with these five stocks to buy for 500% upside potential.
Via
InvestorPlace
Editas' Gene Editing Treatment Shows Initial Safety, Efficacy In Patients With Rare Blood Disorders
June 09, 2023
Editas Medicine Inc (NASDAQ: EDIT) annou
Via
Benzinga
Editas Medicine Announces Positive Initial EDIT-301 Safety and Efficacy Data from the First Four Patients Treated in the RUBY Trial and the First Patient Treated in the EdiTHAL Trial
June 09, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Why Are Gene Editing Stocks EDIT, NVTA, CRSP Up Today?
June 06, 2023
Gene editing stocks are up today on news that Editas Medicine will present clinical data on June 12. Here's what this means for the sector.
Via
InvestorPlace
Editas Medicine to Host Virtual Event to Discuss EDIT-301 Clinical Data from the RUBY Trial for Severe Sickle Cell Disease and the EDITHAL Trial for Transfusion-dependent Beta Thalassemia
June 06, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Genprex (NASDAQ: GNPX) Releases New Patient Video Interview Describing Positive Experience in Clinical Trial
June 01, 2023
A clinical-stage gene therapy company is making splashes in the medical world. Genprex, Inc. (NASDAQ: GNPX) is developing potentially life-changing therapies for patients with cancer and diabetes that...
Via
Benzinga
7 Short-Squeeze Stocks Set for a May Rally
May 22, 2023
While targeting the best short-squeeze stocks to buy now can be incredibly treacherous, they may also yield robust returns.
Via
InvestorPlace
Cathie Wood Is Buying This Biotech Stock Like Wildfire, But Should You?
May 21, 2023
It's facing a few issues that are practically guaranteed to affect shareholder returns.
Via
The Motley Fool
Editas Medicine Reports Inducement Grant to New Chief Financial Officer
May 18, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces Appointment of Erick J. Lucera as Chief Financial Officer
May 16, 2023
Michelle Robertson to remain with Company until August 16, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
ONEOK, PacWest Bancorp And Other Big Stocks Moving Lower In Monday's Pre-Market Session
May 15, 2023
U.S. stock futures traded higher this morning. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.